Warning Letters issued by the U.S. Food and Drug Administration (FDA) after Bioresearch Monitoring (BIMO) inspections identified seven common deficiencies related to institutional review board (IRB) activities, according to a report from the agency. The agency did not rank the deficiencies in any order. Those cited:
- Inadequate initial and/or continuing review of studies
- Inadequate […]